Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments
Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Nov. 25, 2025. Document 2025-21071. Updated Nov. 17, 2026.
- What it does
The Food and Drug Administration (FDA) is proposing to reclassify certain postamendments class III nucleic acid-based test systems indicated for use with a corresponding approved oncology therapeutic product (product codes OWD, PJG, PQP, and SFL) from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.
The Food and Drug Administration's summary, as published in the Federal Register.
- What it would change
1 part of Title 21 of the Code of Federal Regulations:
- What happens next and when
Submit electronic or written comments on the proposed order by January 26, 2026. Please see section X of this document for the proposed effective date when the new requirements apply and for the proposed effective date of a final order based on this proposed order.
The agency's dates, word for word.
The record as published
| Document number | 2025-21071 |
|---|---|
| Action | Proposed amendment; proposed order; request for comments. |
| Agencies | Health and Human Services Department; Food and Drug Administration |
| Published | Nov. 25, 2025 |
| Comments close | Jan. 26, 2026 |
| Docket | FDA-2025-N-4622 |
Source: the Federal Register (public domain). The document in the Federal Register